Detailed Programme
Wednesday, 23 November 2022 |
||
| 14:00 | Platform opening | |
|
|
Opening of the Meeting
|
|
Session 1 – Structural aspects of drug designChairman: Višnja Stepanić |
||
|
15:30–16:15
|
PL-1
|
Martin Smieško (University of Basel, Switzerland)
Designing Safer Drugs: Structure-Based Methods in Predicting Off-target Binding |
|
16:15–16:35
|
L-1
|
Silvia Salerno (University of Pisa, Italy)
Indole-based derivatives as carbonic anhydrase activators for neurodegeneration diseases |
|
16:35–17:20
|
PL-2
|
Peter Ertl (Novartis Institutes for BioMedical Research in Basel, Switzerland)
Magic Rings: Navigation in the Chemical Space of Bioactive Rings |
|
17:20–17:40
|
L-2
|
Valeria Pittala (University of Catania, Italy)
Progress in the development of novel heme oxygenase-1 inhibitors with potent anti-proliferative activity |
|
||
Session 2 – New compounds in combating infectious diseasesChairman: Gabriele Costantino |
||
|
09:00–09:45
|
PL-3
|
Giannamaria Annunziato (University of Parma, Italy)
Dealing with anti-microbial resistance (AMR) by taking advantage of cysteine biosynthesis inhibitors as antimicrobial adjuvants |
|
09:45–10:15
|
KL-1
|
Stella Maria Cascioferro (University of Palermo, Italy)
Anti-virulence agents with anti-biofilm mechanism of action to counteract antibiotic resistance in grampositive pathogens |
|
10:15–10:45
|
Coffee break
|
|
Session 3 – Structural insights in new antibacterial drugsChairman: Michael Schnürch |
||
|
10:45–11:30
|
PL-4
|
Jan Zitko (Charles University, Czechia)
Biological properties of pyrazinamide derivatives: Antimicrobial activity and beyond |
|
11:30–12:00
|
KL-2
|
Katharina Pallitsch (University of Vienna, Austria)
Organic chemistry as a potent tool to study human metabolism |
|
12:00–12:20
|
L-3
|
Azzurra Stefanucci (University “Gabriele d’Annunzio”, Italy)
Discovery of new teixobactin analogues with total lactam bridge |
|
12:20–14:00
|
Lunch
|
|
|
14:00–15:00
|
Poster Session I (odd numbers)
|
|
Session 4 – Compounds with antiviral potencyChairman: Jan Zitko |
||
|
15:00–15:45
|
PL-5
|
Anikó Borbás (University of Debrecen, Hungary)
Emerging roles of glycopeptide antibiotics: teicoplanin and vancomycin derivatives with enhanced antibacterial and antiviral activities |
|
15:45–16:05
|
L-4
|
Simona Musella (University of Salerno, Italy)
Rational design of the zonulin inhibitor AT1001 derivatives as potential SARS-COV-2 clinical candidates for intranasal administration |
|
16:05–16:35
|
Coffee break
|
|
Session 5 – Searching for new targets for drug designChairman: Magdaléna Májeková |
||
|
16:35–16:55
|
L-5
|
Arianna Gelain (University of Milan, Italy)
Development of a novel approach to overcome biofilm formation by natural product derivatives |
|
16:55–17:15
|
L-6
|
Marta Giorgis (Turin University, Italy)
Important steps into drug development of MEDS433, a potent human dihydroorotate dehydrogenase inhibitor based on the 2-hydroxypyrazole[1,5-A] pyridine scaffold |
| 17:15–17:35 | L-8 | Ana Penava (University of Zagreb, Croatia) Synthesis of new generation of harmiquins, harmine and chloroquine hybrids as potential antiplasmodial agents |
|
||
Session 6 – The role of organic chemistry in drug design I.Chairman: Lucia Kováčiková |
||
|
08:30–09:15
|
PL-6
|
Nela Malatesti (University of Rijeka, Croatia)
The tale of the lipophilic tail of the meso-tripyridinium porphyrins in the photodynamic action |
|
09:15–09:45
|
KL-3
|
Sándor Balázs Király (University of Debrecen, Hungary)
Domino cyclization reactions for the preparation of condensed heterocycles with antiproliferative activity |
|
09:45–10:15
|
Coffee break
|
|
Session 7 – Compounds for treatment of CNS disordersChairman: Dariusz Matosiuk |
||
|
10:15–11:00
|
PL-7
|
Marcin Kolaczkowski (Jagiellonian University of Cracow, Poland)
Biased agonists of the 5-HT1A receptor – a new hope for addressing treatment-resistant depression? |
|
11:00–11:30
|
KL-4
|
Slawomir Filipek (University of Warsaw, Poland)
Allosteric and ortho-allosteric modulation of G protein-coupled receptors |
|
11:30–12:00
|
KL-5
|
Urban Košak (University of Ljubljana, Slovenia)
Selective inhibitors of butyrylcholinesterase for alleviating symptoms of Alzheimer’s disease |
| 12:00–12:20 | L-9 | Halilibrahim Ciftci (Koc University, Istanbul, Turkey) Development of next-generation drug candidates for ALS treatment |
|
12:20–13:30
|
Lunch
|
|
|
13:30–14:30
|
Poster session II (even numbers)
|
|
Session 8 – The role of organic chemistry in drug design II.Chairman: Peter Šramel |
||
|
14:30–15:00
|
KL-6
|
Andrej Emanuel Cotman (University of Ljubljana, Slovenia)
Chiral going viral: Asymmetric catalysis paves the way for improved property lead compounds |
|
15:00–15:30
|
KL-7
|
Đani Škalamera (University of Zagreb, Croatia)
Synthesis and immunoadjuvant activity of QS-7 analogs with truncated linear saccharide domain |
| 15:30–15:50 | L-10 | Walter Kuba (TU Wien, Austria) Boosting bioorthogonal bond-cleavage reactions of tetrazines and trans-cyclooctenes via intramolecular interactions |
|
15:50–16:20
|
Coffee break
|
|
Session 9 – Specific targets in metabolic, CNS and inflammation disordersChairman: Marcin Kolaczkowski |
||
|
16:20–16:50
|
KL-8
|
Milan Štefek (Slovak Academy of Sciences, Slovakia)
Novel indole-based bifunctional aldose reductase inhibitors/antioxidants as promising drugs for treatment of diabetic complications |
|
16:50–17:20
|
KL-9
|
Tana Tandarić (University of Uppsala, Sweden & Ruder Boskovic Institute, Croatia)
An insight into the mechanism of the irreversible inhibition of monoamine oxidase enzymes by propargylamine inhibitors |
|
17:20–17:40
|
L-11
|
Tania Ciaglia (University of Salerno, Italy)
New indoline-based 5-LOX/she dual inhibitors: in vitro and in vivo pharmacological characterization |
| 17:40–18:00 | L-12 | Angela Corvino (University of Naples «Federico II», Italy) Molecular hybrids between corticosteroids and H2S domains as a new therapeutic option for inflammatory disorders |
|
||
Session 10 – Structural aspects of ligand bindingChairman: Emmanuel Mikros |
||
|
09:00–09:45
|
PL-8
|
Marko Anderluh (University of Ljubljana, Slovenia)
Novel DNA gyrase inhibitors bind asymmetrically to their target using symmetrical bifurcated halogen bonds |
|
09:45–10:15
|
KL-10
|
Josef Jampílek (Comenius University, Bratislava, Slovakia)
Investigations of new derivatives of β-hydroxyarylcarboxylic acids |
|
10:15–10:45
|
|
Dionysia Papagiannopoulou (University of Thessaloniki, Greece)
Technetium-99m tracers towards the development of molecular imaging agents |
|
10:45–11:05
|
L-13
|
Gabriella La Spada (University of Bari Aldo Moro, Italy)
Structure-based design of phenyl ring bioisosteres: selectivity switch in dual AChE-MAO B and BChE-MAO B inhibitors |
|
11:05–11:35
|
Coffee break
|
|
Session 11 – Perspective ligands for cancer treatmentChairman: Marko Anderluh |
||
|
11:35–11:55
|
L-14
|
Letizia Giampietro (University of Chieti-Pescara “G. d’Annunzio”, Italy)
New synthesized phenyldiazenyl sulphonamides as aromatase inhibitors |
|
11:55–12:15
|
L-15
|
Veronica Di Sarno (University of Salerno, Italy)
TRPM8 antagonists as new potential therapeutics in castration-resistant prostate cancer (CRPC) |
| 12:15–12:35 | L-16 | Maria Dichiara (Northeastern University, Boston, Massachusetts, USA) Imidazopyridine derivatives for visceral Leishmaniasis: Synthesis and structure-property optimization |
|
12:35–13:05
|
Winning Posters Flash presentations
|
|
|
13:05–13:35
|
Closing
|
|
Last update on 18 November 2022.
The programme might be subject to necessary changes.